ESElizabeth M. Sherman

Elizabeth M. Sherman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth M. Sherman has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 Infection

    by Elias B. Chahine, John J. Faragon, Nimish Patel, Elizabeth M. Sherman

    Objective: To evaluate the efficacy and safety of bictegravir/lenacapavir for the treatment of HIV-1 infection. Data Sources: A literature search was conducted in PubMed and Google Scholar (January 2016-August 2026) using the search terms bictegravir and lenacapavir . Other data sources included abstracts presented at recent conferences and the prescribing information. Study Selection and Data Extraction: All English-language studies assessing the efficacy and safety of bictegravir/lenacapavir for the treatment of HIV-1 infection were considered for inclusion. Data Synthesis: Bictegravir is an established second-generation integrase strand transfer inhibitor (INSTI), whereas lenacapavir is a novel capsid inhibitor. Both antiretrovirals are highly active against HIV-1. Bictegravir/lenacapavir 75 mg/50 mg was shown to be safe and effective in two phase 3 clinical trials after switching from complex antiretroviral therapy (ART) or bictegravir/emtricitabine/tenofovir alafenamide. The Food and Drug Administration approved this combination for the treatment of HIV-1 infection in adults who are virologically suppressed on stable ART with no resistance to the individual components. It is available as a single-tablet regimen (STR) taken orally once daily. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: Bictegravir/lenacapvir is the first INSTI-capsid inhibitor 2-drug STR indicated for the treatment of HIV-1 infection. The combination could be useful for patients who want to simplify their regimen and/or those who cannot use a nucleos(t)ide or a non-nucleoside reverse transcriptase inhibitor. It is not active against hepatitis B virus coinfection. Conclusions: Bictegravir/lenacapvir is safe and efficacious as a 2-drug regimen for the treatment of adults with HIV-1 infection.

  • Open Access

    Pharmacist's role in managing drug–drug interactions in people with HIV receiving antiretroviral therapy or HIV pre‐exposure prophylaxis: A focus on polypharmacy and transitions of care in the United States

    by Shawnalyn W. Sunagawa, Elizabeth M. Sherman, Melissa Badowski, David B. Cluck, Spencer H. Durham, Joshua P. Havens, Emily Huesgen, Justin K. Ma, Roxane Rohani, Eric G. Sahloff, et al.

  • Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection

    by Elias B. Chahine, David E. Koren, Rafik Samuel, Harrison Van der Kloot, Elizabeth M. Sherman

    Objective: The objective of this study is to review the efficacy and safety of doravirine/islatravir for the treatment of HIV-1 infection. Data Sources: A literature search was conducted in PubMed and Google Scholar (January 2016–June 2026) using the search terms doravirine or MK-1439 and islatravir or MK-8591 . Other resources included abstracts presented at recent conferences and the prescribing information. Study Selection and Data Extraction: All English-language studies assessing the efficacy and safety of doravirine/islatravir for the treatment of HIV-1 infection were included. Data Synthesis: Doravirine is an established second-generation nonnucleoside reverse transcriptase inhibitor. Islatravir is a new nucleoside reverse transcriptase inhibitor that uniquely interferes with translocation and is highly active against HIV-1. Doravirine/islatravir once daily was shown to be safe and effective in three phase 3 clinical trials, using a lower dose of islatravir (0.25 mg), after a higher dose (0.75 mg) was shown in earlier trials to reduce total lymphocyte and CD4+ T-cell counts. The FDA approved this combination for the treatment of HIV-1 infection in adults who are virologically suppressed on stable antiretroviral therapy with no history of virologic treatment failure and no known resistance to doravirine. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Doravirine/islatravir is the first integrase strand transfer inhibitor-free 2-drug regimen indicated for the treatment of HIV-1 infection. The combination could be useful for patients who want to simplify their regimen and those who cannot receive an integrase inhibitor. Conclusions: Doravirine/islatravir is safe and effective as a 2-drug regimen for the treatment of HIV-1 infection.

  • Need for More HIV ‐Trained Pharmacists due to Unmet Needs and Expanding Opportunities: An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy

    by Radhika S. Polisetty, Spencer H. Durham, Roxane Rohani, David B. Cluck, Elizabeth Sherman, Crystal K. Hodge, Emily Huesgen, Eric Sahloff, Salin Nhean, Melissa Badowski, et al.

    According to the Centers for Disease Control and Prevention, 1.2 million people are living with human immunodeficiency virus (HIV) in the United States, and an estimated 32 000 new HIV infections are reported each year. While pharmacists and pharmacies play major roles in ending the HIV epidemic, harnessing their full potential will require substantial investment in training qualified pharmacy personnel who can provide HIV prevention and treatment services encompassing comprehensive, culturally sensitive care. The purpose of this white paper is to review critical challenges facing the profession of pharmacy that hinder comprehensive HIV care, including the paucity of residency‐trained HIV pharmacists due to a lack of HIV‐focused post‐graduate training programs, inconsistencies in pharmacy curricula, and insufficient or variable reimbursement for pharmacist services. By proposing targeted solutions across pharmacy education, training, research, and reimbursement, we seek to cultivate a robust, well‐trained pharmacy workforce who can effectively provide HIV prevention and treatment services.


  • Open Access

    Exploring workflows for long-acting antiretroviral therapy administration in community pharmacies

    by Valerie Clinard, Kevin Bumanglag, Parya Saberi, Kelly Hester, Michael Sigua, George Udeani, Elizabeth Sherman, Yvette Cuca, Jennifer Cocohoba


  • The Role of Clinical Pharmacists in HIV Treatment and Prevention: A Scoping Review of Real‐World Evidence

    by Jenna Januszka, Daniel B. Chastain, Melissa E. Badowski, Marisa Brizzi, Emily N. Drwiega, Spencer H. Durham, Samantha Kaplan, Chelsea A. Keedy, Eric G. Sahloff, Elizabeth M. Sherman, et al.

    Background: Over the past decade there have been notable expansions in pharmacist roles in the treatment and prevention of human immunodeficiency virus (HIV). This review aims to describe pharmacist‐led interventions and their integration into team‐based models at each point in the HIV care continuum. Methods: A systematic search of MEDLINE via Ovid, Embase via Elsevier, and Web of Science Core Collection (Clarivate) was conducted to identify studies that described pharmacists' involvement in HIV care and pre‐exposure prophylaxis. Each identified article was independently reviewed by two of ten clinical pharmacists. Results: From 14 650 articles originally identified, 137 articles were deemed to meet inclusion. Of these, 58 were utilized by the authors in this review. Discussion: The published data included in this review demonstrate the positive impact pharmacists have on HIV treatment and prevention.

  • Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis

    by David E. Koren, Elias B. Chahine, Elizabeth M. Sherman

    Objective: To review the efficacy and safety of lenacapavir for the prevention of HIV-1 infection. Data Sources: Clinical trials and review articles were obtained through August 2025 using search terms lenacapavir, GS-CA1, GS-6207, capsid inhibitor, preexposure prophylaxis, and PrEP. Study Selection and Data Extraction: All relevant articles, trials, and abstracts in the English language were included. Data Synthesis: Lenacapavir uses a novel mechanism for HIV prevention administered through subcutaneous injection. In a counterfactual design, lenacapavir arms demonstrated superior efficacy for prevention against a background HIV incidence rate across a variety of populations and gender identities. Adverse events commonly reported include injection-site reactions, which may include nodules, pain, or swelling at the injection site. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: The extended dosing frequency of lenacapavir may uniquely serve patients at risk of HIV acquisition who are unable or unwilling to take oral prevention medications. The mechanism of action for lenacapavir is not duplicative of other medications used in first-line antiretroviral regimens and thus may not risk resistance to regularly used classes if resistance occurs. Lenacapavir is a moderate cytochrome P450 inhibitor and thus may have interactions with other medications; however, neither renal nor hepatic dose adjustments are required. Conclusions: Lenacapavir provides a long-acting injectable option for people seeking a pharmacologic prevention agent against HIV-1. Despite injection-site reactions being relatively common, these did not present a barrier to treatment continuation among trial participants.


  • Open Access

    Preparing for pharmacy-based delivery of long-acting injectable antiretrovirals: a pre-implementation study

    by Jennifer Cocohoba, Yvette Cuca, Elizabeth Sherman, Kelly Hester, George Udeani, Michael Sigua, Parya Saberi

    Background: Use of long-acting injectable antiretroviral therapy (LA-ART) for human immunodeficiency virus (HIV) treatment and prevention is increasing, but there are challenges that could limit broad expansion of these important treatments. The goal of this study was to explore attitudes, barriers, and facilitators for implementing LA-ART administration within community pharmacies. Methods: We conducted a mixed-methods study focusing on pre-implementation aspects of community pharmacy-administered LA-ART. Pharmacists, clinic staff members, and persons with HIV completed a baseline survey followed by an individual semi-structured qualitative interview with questions based on the Consolidated Framework for Implementation Research (CFIR v.1.0). Results: A total of 63 participants (pharmacist n = 19, clinic staff n = 20, person with HIV n = 24) from Alabama, California, Florida, and Texas were included in the study. Most pharmacist participants were employed in retail pharmacies that processed fewer than 500 prescriptions per day (75%) and most had more than 10 years of experience working with people with HIV (53%). Clinic staff participants were also highly experienced in working with people with HIV (55%). People with HIV enrolled in the study were either on oral antiretroviral therapy but interested in LA-ART (59%) or were already on LA-ART (29%). Clinics were the preferred location for LA-ART administration while community pharmacy was the second preferred location. Attitudes regarding pharmacy-based administration of LA-ART were mostly positive, with the primary facilitator being positive experiences or established relationships between clinics and pharmacies or persons with HIV and their pharmacies. Barriers included concerns about pharmacy staffing, training, space, privacy, and pharmacy reimbursement for services. Conclusion: Involving community pharmacies in the administration of LA-ART could expand access to HIV treatment and prevention medications. Outlining best practices that leverage facilitators and overcome barriers can help clinics, pharmacy, and communities expand this novel model of care. Trial registration: ClinicalTrials.Gov Registration: NCT05152953 (posted 12/10/2021).


  • Open Access

    Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV : A systematic literature review and network meta‐analysis

    by Ishfaq Rashid, Nathan R. Unger, Connor Willis, Teerapon Dhippayom, Moti Ramgopal, Elizabeth M. Sherman, Nicholas Yared, Rachel Safran, Edwin Swiatlo, Amy R. Weinberg, et al.

    Objective: This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV. Methods: A systematic literature review was conducted for phase 2–4 randomized controlled trials with ≥48 weeks of follow‐up involving virologically suppressed people with HIV aged ≥12 years and published January 2003–March 2024. A random‐effects network meta‐analysis estimated comparative rates of TE‐RAMs and DC‐AEs among regimens at 48 weeks. Risk of bias and strength of evidence were assessed using Cochrane RoB and CINeMA, respectively. Results: Fourteen (7509 participants) and nine (4656 participants) studies were included in the TE‐RAMs and DC‐AEs analyses, respectively. No significant differences in rates of TE‐RAMs were observed; risk ratios (RRs) for TE‐RAMs for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) and CAB + RPV every 4 weeks (Q4W) versus CAB + RPV every 8 weeks (Q8W) were 0.22 (95% CI, 0.02–2.04), 0.22 (95% CI, 0.00–19.85) and 0.40 (95% CI, 0.14–1.09). Compared with CAB + RPV Q4W and Q8W, DC‐AEs were significantly lower with B/F/TAF (RR, 0.15 [95% CI, 0.03–0.75] and RR, 0.16 [95% CI, 0.04–0.67], respectively) and DTG/ABC/3TC (RR, 0.05 [95% CI, 0.01–0.48] and RR, 0.05 [95% CI, 0.01–0.46], respectively). Conclusions: In virologically suppressed people with HIV, switching to CAB + RPV Q8W yielded a non‐significant increased risk of TE‐RAMs compared with INSTI‐based 2‐ and 3‐drug regimens and CAB + RPV Q4W. Both CAB + RPV Q4W and Q8W had significantly higher risks of DC‐AEs than B/F/TAF and DTG/ABC/3TC. Findings highlight the importance of considering both resistance and tolerability when switching regimens.


  • Open Access

    Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists

    by Elizabeth M. Sherman, Allison L. Agwu, Juan Ambrosioni, Georg M. N. Behrens, Carolyn Chu, Lauren F. Collins, Humberto R. Jimenez, David E. Koren, Leslie McGorman, Nancy N. Nguyen, et al.

    Five long‐acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV‐1 prevention or treatment—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV‐1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV‐1 treatment and prevention. In addition, future areas of research are also identified and discussed.